Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Work In Process (2018 - 2025)

Historic Work In Process for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $1.6 million.

  • TransMedics' Work In Process fell 6651.67% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 6651.67%. This contributed to the annual value of $3.3 million for FY2024, which is 1397.79% down from last year.
  • Latest data reveals that TransMedics reported Work In Process of $1.6 million as of Q3 2025, which was down 6651.67% from $3.9 million recorded in Q2 2025.
  • TransMedics' Work In Process' 5-year high stood at $4.9 million during Q3 2024, with a 5-year trough of $1.3 million in Q2 2021.
  • Over the past 5 years, TransMedics' median Work In Process value was $2.5 million (recorded in 2022), while the average stood at $2.8 million.
  • In the last 5 years, TransMedics' Work In Process skyrocketed by 10287.85% in 2023 and then crashed by 6651.67% in 2025.
  • Quarter analysis of 5 years shows TransMedics' Work In Process stood at $1.9 million in 2021, then decreased by 2.9% to $1.9 million in 2022, then skyrocketed by 102.88% to $3.8 million in 2023, then decreased by 13.98% to $3.3 million in 2024, then tumbled by 50.0% to $1.6 million in 2025.
  • Its Work In Process stands at $1.6 million for Q3 2025, versus $3.9 million for Q2 2025 and $3.8 million for Q1 2025.